Skip to main content
REGN logo

Regeneron Pharmaceuticals, Inc.

REGNNASDAQHealthcareBiotechnology

$805.02Today:- (-)1Y +42.28%

As of Oct 23, 2026 close

Market cap
$85.33B
P/E (TTM)
19.71
Forward P/E
20.87
Dividend yield
0.45%
52-week range
$572.75$859.34
Volume (live)
-
Avg. volume (3M)
731.62K

Regeneron Pharmaceuticals, Inc. (REGN) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Regeneron Pharmaceuticals, Inc. stock.

Analyst Consensus Rating

Investment consensus from 26 professional research analysts

Consensus Rating

Buy
Based on 26 unique analysts
(38 total ratings in last 90 days)
Very High Confidence8.0:1 Buy/Sell

Average Price Target

$863.45
+7.26% upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest REGN Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Tyler Van Buren
TD Cowen
BuyMaintains
$960.00 → $980.00
David Risinger
Leerink Partners
HoldMaintains
$824.00 → $835.00
Biren Amin
Piper Sandler
BuyMaintains
$854.00 → $865.00
Mohit Bansal
Wells Fargo
HoldMaintains
$750.00
Zacks Equity Research
Zacks Equity Research
BuyInitiates Coverage
-
Louise Chen
Scotiabank
HoldMaintains
$770.00
Joon Lee
UBS
BuyInitiates
$660.00 → $978.00
Tazeen Ahmad
BofA Securities
BuyReiterates
$891.00 → $908.00
Evan Seigerman
BMO Capital
BuyMaintains
$920.00
Geoff Meacham
Citi
HoldMaintains
$740.00
Zacks Equity Research
Zacks Equity Research
BuyInitiates Coverage
-
Brian Abrahams
RBC Capital
HoldMaintains
$737.00 → $810.00
Gregory Renza
Truist
BuyMaintains
$772.00 → $780.00
Terence Flynn
Morgan Stanley
HoldReiterates
$779.00
Chris Schott
JP Morgan
BuyReiterates
$900.00 → $950.00
Louise Chen
Scotiabank
HoldMaintains
$770.00
Biren Amin
Piper Sandler
BuyMaintains
$854.00
Gregory Renza
Truist
BuyMaintains
$772.00
David Risinger
Leerink Partners
HoldMaintains
-
Salveen Richter
Goldman Sachs
BuyMaintains
$972.00
Eliana Merle
Barclays
BuyMaintains
$917.00
Tazeen Ahmad
BofA Securities
BuyMaintains
$891.00
Geoff Meacham
Citi
HoldMaintains
$740.00
Brian Skorney
Baird
HoldMaintains
$761.00
Akash Tewari
Jefferies
BuyMaintains
$870.00 → $930.00
Salveen Richter
Goldman Sachs
BuyMaintains
$972.00
Tazeen Ahmad
BofA Securities
BuyMaintains
$891.00
Evan Seigerman
BMO Capital
BuyMaintains
$800.00 → $920.00
Jasper Hellweg
Argus Research
BuyDowngrades
$850.00
Mohit Bansal
Wells Fargo
HoldMaintains
$750.00
Eve Burstein
Bernstein
HoldMaintains
$756.00
Rajesh Kumar
HSBC
BuyMaintains
$800.00 → $920.00
Kinjel Shah
Zacks Equity Research
SellInitiates Coverage
-
Sundeep Ganoria
Zacks Equity Research
SellInitiates Coverage
-
Yatin Suneja
Guggenheim
BuyMaintains
$1000.00 → $1030.00
Carter Gould
Cantor Fitzgerald
BuyMaintains
$750.00 → $795.00
Tyler Van Buren
TD Cowen
BuyMaintains
$960.00
Deepanwita Sarkar Saha
Zacks Equity Research
BuyInitiates Coverage
-

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 21, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for REGN?

The analyst consensus rating for REGN is Buy, based on the latest ratings from 26 analysts over the last 90 days.

What is the average price target for REGN?

The average 12-month price target for REGN is $863.45, representing an upside of 7.3% from the Oct 23, 2026 close of $805.02.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.